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Background: Increased number of endothelial (EMP) and platelet (PMP) microparticles has been related to cardiovascular risk factors and 
coronary heart disease. Little is known regarding early effects of statins and clopidogrel on these new biomarkers of vascular homeostasis. Our study 
evaluated pharmacokinetic interactions between atorvastatin and clopidogrel and their effects, alone or combined, on EMP, PMP, and endothelial 
progenitor cells (EPC). 
Methods: A prospective open-label study enrolled subjects with stable coronary disease (n=26). Drugs were given daily for 3 weeks (atorvastatin 
80 mg, visit 1-3; clopidogrel 75 mg, visit 2-4). Counts of EPC (CD34+/CD133+/KDR+), EMP (CD51+) and PMP (CD42+/CD31+), and 
pharmacokinetic parameters over 24h were assessed at each visit. 
Results: Atorvastatin plasma concentrations were increased by concomitant therapy with clopidogrel (Cmax, p=0.002; AUClast, p=0.03). After 
atorvastatin withdrawal there was an increase in clopidogrel plasma concentrations (Cmax, p=0.009; AUClast, p=0.039). PMP were inversely 
correlated with clopidogrel Cmax on visit 3 (rho=-0.57, p=0.006) and visit 4 (rho=-0.54, p=0.01), and with clopidogrel AUClast on visit 3 (rho=-0.44, 
p=0.04), and visit 4 (rho=-0.57, p=0.005). In addition, clopidogrel Cmax was correlated with EPC (CD133+/KDR+) on visit 4 (rho=0.48, p=0.025). 
No correlations of atorvastatin and MP or EPC were found. 
Conclusions: The balance between platelet MP release and EPC mobilization seems influenced by clopidogrel plasma levels, suggesting a 
protective mechanism on coronary heart disease.
